Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($0.54), $0.13 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $6.28 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Rothschild Redburn Upgrades Apple (AAPL) to Buy
• Morgan Stanley Starts Target Hospitality (TH) at Overweight